PDCD1 and cancer: Finally, as CAFs have been identified as CD73 highly expressing cells [189], blocking this ectonucleotidase is probably a way of choice to hamper CAFs immunosuppressive effects, in synergy with anti-PD-1 or anti-CTLA-4 antibodies [270–272], cancer vaccines [273] or CAR T cells [274].